Quarterly report · Q3
4548.TEDINET S100SWGL
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥26.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥3.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.0bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.0bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.7bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥79.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥76.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.2bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥71.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥69.8bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.5bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥49.51 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.97 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.42 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.88 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 89.8% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥7.7bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥7.7bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥785m |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥19.7bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥19.7bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.5bn |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥27.4bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥27.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥2.3bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥18.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥26.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥26.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 386
| Item | Context | Value | Unit |
|---|---|---|---|
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)生化学工業株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都千代田区丸の内一丁目6番1号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies na quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes quarterly consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |